Albumin-bound nanoparticles of practically water-insoluble antimalarial lead greatly enhance its efficacy

International Journal of Pharmaceutics

Volumn 464, Issue 1-2, 2014, Pages 214-224

  Ibrahim, Nehal ^a   Ibrahim, Hany ^a   Dormoi, Jerome ^b,c   Briolant, Sébastien ^b,c   Pradines, Bruno ^b,c   Moreno, Alicia ^d,e   Mazier, Dominique ^d,e,f   Legrand, Philippe ^g   Nepveu, Françoise ^a  

^a Hôpital Purpan   (France)

^b INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSERM   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CNRS   (France)

Author keywords

Antimalarial; High pressure homogenization; Human serum albumin; Indolone N oxides; Nanoparticles

Indexed keywords

ALBUMIN; ANTIMALARIAL AGENT; ARTESUNATE; CHLOROQUINE; CLODRONIC ACID; HUMAN SERUM ALBUMIN; INDOLONE N OXIDE NANOPARTICLE; MONOCLONAL ANTIBODY; NANOPARTICLE; NIMP R14; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; ERYTHROCYTE; FEMALE; FREEZE DRYING; IONIC STRENGTH; LOW DRUG DOSE; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PARASITEMIA; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SURVIVAL TIME; TRANSMISSION ELECTRON MICROSCOPY; WETTABILITY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

ANTIMALARIAL; HIGH PRESSURE HOMOGENIZATION; HUMAN SERUM ALBUMIN; INDOLONE-N-OXIDES; NANOPARTICLES;

ANIMALS; ANTIMALARIALS; FEMALE; HUMANS; MALARIA; MICE; MICE, INBRED BALB C; NANOPARTICLES; PLASMODIUM BERGHEI; SERUM ALBUMIN; SOLUBILITY; TREATMENT OUTCOME; WATER;

EID: 84896711205     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.01.001     Document Type: Article

References (54)

1. A. Borjesson, and K. Bolton First principles studies of the effect of Ostwald ripening on carbon nanotube chirality distributions ACS Nano 5 2011 771 779
2. J. Boyer, V. Bernardes-Genisson, and V. Farines et al. 2-Substituted-3H-indol-3-one-1-oxides: preparation and radical trapping properties Free Radic. Res. 38 2004 459 471 (Pubitemid 38618367)
3. J. Chadwick, R.K. Amewu, and F. Marti et al. Antimalrial mannoxanes: hybrid antimalarial drugs with outstanding oral activity profiles and a potential dual mechanism of action ChemMedChem 6 2011 1357 1361
4. W. Chen, B. Gu, and H. Wang et al. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles Int. J. Pharm. 362 2008 133 140
5. F. Cosledan, L. Fraisse, and A. Pellet et al. Selection of a trioxaquine as an antimalarial drug candidate Proc. Natl. Acad. Sci. U.S.A. 105 2008 17579 17584
6. L. Cui, G. Yan, and J. Sattabongkot et al. Malaria in the Greater Mekong subregion: heterogeneity and complexity Acta Trop. 121 2012 227 239
7. Desai, N.P., Tao, C., Yang, A., et al., 29 June 1999. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. US Patent 5,916,596.
8. C. Duranton, V. Tanneur, and C. Lang et al. A high specificity and affinity interaction with serum albumin stimulates an anion conductance in malaria-infected erythrocytes Cell. Physiol. Biochem. 22 2008 395 404
9. A. El Tahir, P. Malhorta, and V.S. Chauhan Uptake of proteins and degradation of human serum albumin by Plasmodium falciparum-infected erythrocytes Malaria J. 2 2003 11
10. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
11. D.A. Fidock, P.J. Rosenthal, and S.L. Croft et al. Drug discovery: efficacy models for compound screening Nat. Rev. Drug Discov. 3 2004 509 520 (Pubitemid 38807533)
12. H. Foster, M. Hooper, and S.H. Imam et al. Increased inhibitory action against adenosine 5′-triphosphate in the isolated taenia of the Guinea-Pig caecum by substitution in the A-ring of 2-phenylisatogen Br. J. Pharmacol. 79 1983 273 278 (Pubitemid 13128997)
13. F.J. Gamo, L.M. Sanz, and J. Vidal et al. Thousands of chemical starting points for antimalarial lead identification Nature 465 2010 305 310
14. L. Gao, D. Zhang, and M. Chan Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system J. Nanopart. Res. 10 2008 845 862
15. A. Hawe, and W. Freiss Physicochemical characterization of the freezing behaviour of mannitol-human serum albumin formulations AAPS PharmSciTech 7 2006 94
16. C. He, Y. Hu, and L. Yin et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 31 2010 3657 3666
17. M. Hooper, D.A. Patterson, and D.G. Wibberley Preparation and antibacterial activity of isatogens and related compounds J. Pharm. Pharmacol. 17 1965 734 741
18. N.K. Ibrahim, N. Desai, and S. Legha et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin. Cancer Res. 8 2002 1038 1044 (Pubitemid 34517637)
19. N. Ibrahim, H. Ibrahim, and S. Kim et al. Interactions between antimalarial indolone-N-oxide derivatives and human serum albumin Biomacromolecules 11 2010 3341 3351
20. H. Ibrahim, A. Pantaleo, and F. Turrini et al. Pharmacological properties of indolone-N-oxides controlled by a bioreductive transformation in red blood cells? Med. Chem. Commun. 2 2011 860 869
21. H. Ibrahim, A. Furiga, and E. Najahi et al. Antibacterial, antifungal and antileishmanial activities of indolone-N-oxide derivatives J. Antibiot. 65 2012 499 504
22. T. Ishihara, M. Takahashi, and M. Higaki et al. Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles Pharm. Res. 7 2008 1686 1695
23. C.C. John, E. Kutamba, and K. Mugarura et al. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria Expert Rev. Anti Infect. Ther. 8 2010 997 1008
24. C.M. Keck, and R.H. Muller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 2006 3 16 (Pubitemid 41736019)
25. Kipp, J.E., Wong, J.C.T., Doty, M.J., et al., 19 August 2003. Microprecipitation method for preparing submicron suspensions. US Patent 6,607,784.
26. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
27. S. Kumar, and D.J. Burgess Nanosuspensions J.C. Wright, D.J. Burgess, Long Acting Injections and Implants 2012 Springer New York 239 261
28. P.V. Kumar, and N.K. Jain Suppression of agglomeration of ciprofloxacin-loaded human serum albumin nanoparticles AAPS PharmSciTech 8 2007 17
29. K. Langer, S. Balthasar, and V. Vogel et al. Optimization of the preparation process for human serum albumin nanoparticles Int. J. Pharm. 257 2003 169 180 (Pubitemid 36507043)
30. Y. Liu, C. Sun, and Y. Hao et al. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles J. Pharm. Pharm. Sci. 13 2010 589 606
31. K. Menton, M. Spedding, and P. Gressens et al. Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2′- pyridylisatogen tosylate and related compounds Eur. J. Pharmacol. 444 2002 53 60 (Pubitemid 34621334)
32. S.M. Moghimi, C.J.H. Porter, and I.S. Muir et al. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating Biochem. Biophys. Res. Commun. 177 1991 861 866
33. A. Moreno, E. Ferrer, and S. Arahuetes et al. The course of infections and pathology in immunomodulated NOD/LtSz-SCID mice inoculated with Plasmodium falciparum laboratory lines and clinical isolates Int. J. Parasitol. 36 2006 361 369 (Pubitemid 43376118)
34. A. Moreno, J.L. Pérignon, and S. Morosan et al. Plasmodium falciparum-infected mice: more than a tour de force Trends Parasitol. 23 2007 254 262
35. R.H. Muller, and J.U. Junghanns Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs V.P. Torchilin, Nanoparticulates as Drug Carriers 2006 Imperial College Press London 307
36. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170 (Pubitemid 39237077)
37. C.J.L. Murray, L.C. Rosenfeld, and S.S. Lim et al. Global malaria mortality between 1980 and 2010: a systematic analysis Lancet 379 2012 413 431
38. C.C. Musonda, G.A. Whitlock, and M.J. Witty et al. Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity Bioorg. Med. Chem. Lett. 19 2009 481 484
39. F. Nepveu, S. Kim, and J. Boyer et al. Synthesis and antiplasmodial activity of new indolone N-oxide derivatives J. Med. Chem. 53 2010 699 714
40. A. Nzila, M. Rottmann, and P. Chitnumsub et al. Preclinical evaluation of the antifolate QN254, 5-chloro-N6-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6- triamine, as an antimalarial drug candidate Antimicrob. Agents Chemother. 54 2010 2603 2610
41. K. Ogawara, M. Yoshida, and K. Higaki et al. Hepatic uptake of polystyrene microspheres in rat: effect of particle size on intrahepatic distribution J. Control. Release 59 1999 15 22 (Pubitemid 29187189)
42. A. Pantaleo, E. Ferru, and R. Vono et al. New anti-malarial indolone-N-oxides, generating stable radical species, promote destabilization of the host cell membrane at early stages of plasmodium falciparum growth Free Radic. Biol. Med. 52 2012 527 536
43. S. Patil, M. Joshi, and S. Pathak et al. Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation J. Antimicrob. Chemother. 67 2012 2713 2716
44. M. Perić, A. Fajdetić, and R. Rupčić et al. Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin J. Med. Chem. 55 2012 1389 1401
45. C.V. Ramana, P. Patel, and K. Vanka et al. A combined experimental and density functional theory study on the Pd-mediated cycloisomerization of O-alkynylnitrobenzenes - synthesis of isatogens and their evaluation as modulators of ros-mediated cell death Eur. J. Org. Chem. 2010 2010 5955 5966
46. K. Reybier, T.H.Y. Nguyen, and H. Ibrahim et al. Electrochemical behavior of indolone-N-oxides: relationship to structure and antiplasmodial activity Bioelectrochemistry 88 2012 57 64
47. A.B. Sahasrabudhe, H.V. Kamath, and B.V. Bapat et al. Antitubercular agents. Part III: synthesis of substituted 2-arylisatogens Indian J. Chem. 19B 1980 230 232
48. H.G. Schroeder, B.A. Bivins, and G.P. Sherman et al. Physiological effects of subvisible microspheres administered intravenously to beagle dogs J. Pharm. Sci. 67 1978 508 513 (Pubitemid 8331312)
49. E.A. Simone, T.D. Dziubla, and V.R. Muzykantov Polymeric carriers: role of geometry in drug delivery Expert Opin. Drug Deliv. 5 2008 1283 1300
50. R. Tahar, L. Vivas, and L. Basco et al. Indolone-N-oxide derivatives: in vitro activity against fresh clinical isolates of Plasmodium falciparum, stage specificity and in vitro interactions with established antimalarial drugs J. Antimicrob. Chemother. 66 2011 2566 2572
51. N. Van Rooijen, and A. Sanders Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications J. Immunol. Methods 174 1994 83 93
52. P.W. Voorhees The theory of Ostwald ripening J. Stat. Phys. 38 1985 231 252
53. N.J. White Artemisinin resistance - the clock is ticking Lancet 376 2010 2051 2052
54. L. Yildirimer, N. Thanh, and M. Loizidou et al. Toxicology and clinical potential of nanoparticles Nano Today 6 2011 585 607